Hypofractionated Radiotherapy After Complete Resection for Stage II/III Thymic Epithelial Tumors (TET-HFRT40)
2026年7月8日 更新者：Tianjin Medical University Cancer Institute and Hospital
A Prospective, Single-Arm Phase II Clinical Study of Hypofractionated Adjuvant Radiotherapy After Complete Resection for Stage II/III Thymic Epithelial Tumors
This is a prospective, open-label, single-arm Phase II study designed to evaluate the safety of postoperative hypofractionated radiotherapy in patients with Stage II/III thymic epithelial tumors after complete resection.
After a screening period of up to 28 days, eligible patients will receive adjuvant hypofractionated radiotherapy to a total dose of 40 Gy in 15 fractions, delivered once daily at 2.67 Gy per fraction, 5 days per week over 3 weeks.
The study will primarily assess treatment-related safety and tolerability, with preliminary evaluation of efficacy, economic burden, and quality of life.
調査の概要
研究の種類
介入
入学 (推定)
49
段階
- フェーズ2
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前：Wencheng Zhang, M.D.
- 電話番号：1121 +86 022 23340123
- メール：zhangwencheng@tjmuch.com
研究場所
-
-
Tianjin Municipality
-
Tianjin、Tianjin Municipality、中国、300060
- 募集
- Tianjin Medical University Cancer Institute and Hospital
-
コンタクト：
- Wencheng Zhang, M.D.
- 電話番号：1121 +86 022 23340123
- メール：zhangwencheng@tjmuch.com
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
説明
Inclusion Criteria:
- Patients who voluntarily agree to participate in this study, sign the informed consent form, demonstrate good compliance, and are willing to comply with scheduled follow-up visits.
- Age 18-75 years, male or female.
- Histopathologically confirmed thymoma or thymic carcinoma after R0 complete resection. Eligible disease stages according to the Masaoka-Koga staging system include Stage II-III thymic carcinoma, Stage IIA Type B3 thymoma, Stage IIB Type B2/B3 thymoma, and Stage III thymoma.
- Eastern Cooperative Oncology Group performance status of 0-1.
- Life expectancy of at least 3 months.
- Adequate major organ function to meet the requirements of study treatment, including bone marrow, hepatic, renal, and coagulation function according to protocol-specified criteria.
- Patients with reproductive potential must agree to use medically acceptable contraception during study treatment and for 6 months after completion of study treatment. Female patients of childbearing potential must have a negative pregnancy test before enrollment and must not be breastfeeding.
Exclusion Criteria:
- Patients who do not meet the protocol-specified requirements for pathological type, disease stage, or histological subtype.
- Patients who have not undergone surgical treatment, or who underwent R1 or R2 resection, or who have definite gross residual disease.
- Prior thoracic radiotherapy.
- Major surgery other than the tumor resection procedure or severe trauma within 4 weeks before the first radiotherapy treatment.
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
- Prior or ongoing non-protocol-specified antitumor therapy, including immunotherapy, targeted therapy, radiotherapy, or other investigational treatment.
- Active autoimmune disease or a history of severe autoimmune disease that, in the investigator's judgment, makes the patient unsuitable for radiotherapy.
- History of immunodeficiency, including HIV positivity, history of organ transplantation, or history of allogeneic bone marrow transplantation.
- Uncontrolled severe cardiovascular disease, such as New York Heart Association Class II or higher heart failure, unstable angina, myocardial infarction within 1 year, or severe arrhythmia requiring clinical intervention.
- Severe infection within 4 weeks before the first radiotherapy treatment, or active pulmonary inflammation indicated by baseline imaging.
- History of interstitial lung disease, history of non-infectious pneumonitis, or Grade 3 or higher pulmonary dysfunction confirmed by pulmonary function testing.
- Active pulmonary tuberculosis, active hepatitis B infection, or active hepatitis C infection.
- Diagnosis of another malignancy before the first radiotherapy treatment, except for low-risk malignancies that have been adequately treated.
- Any other condition that, in the investigator's judgment, may affect patient safety, compliance, or the collection of study data.
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：RT
|
The investigational treatment consists of postoperative hypofractionated radiotherapy delivered at a total dose of 40 Gy in 15 fractions (2.67 Gy per fraction), administered 5 days per week.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of Treatment-Related Grade 2 or Higher Acute Adverse Events
時間枠：Up to 3 months
|
Percentage of participants who experience treatment-related Grade 2 or higher acute adverse events from the start of radiotherapy to 3 months after completion of radiotherapy, assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0).
|
Up to 3 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Disease-Free Survival
時間枠：Up to 3 years
|
Time from the start of radiotherapy to the first documented disease recurrence, distant metastasis, or death from any cause, whichever occurs first.
|
Up to 3 years
|
|
Overall Survival
時間枠：Up to 3 years
|
Time from the start of radiotherapy to death from any cause.
|
Up to 3 years
|
|
Locoregional Recurrence Rate
時間枠：Up to 3 years
|
ercentage of participants who develop locoregional recurrence during follow-up.
Locoregional recurrence includes recurrence in the tumor bed, mediastinum, pleura, or regional lymph nodes, as assessed by imaging, pathology, or clinical evaluation.
|
Up to 3 years
|
|
Distant Metastasis Rate
時間枠：Up to 3 years
|
Percentage of participants who develop distant metastasis during follow-up, as assessed by imaging, pathology, or clinical evaluation.
|
Up to 3 years
|
|
All-Cause Mortality Rate
時間枠：Up to 3 years
|
Percentage of participants who die from any cause during follow-up.
|
Up to 3 years
|
|
Incidence of Treatment-Related Late Adverse Events
時間枠：From 6 months after completion of radiotherapy to 3 years
|
Percentage of participants who experience treatment-related late adverse events occurring 6 months or later after completion of radiotherapy, including pulmonary, cardiac, esophageal, or other late adverse events, assessed according to NCI-CTCAE v5.0.
|
From 6 months after completion of radiotherapy to 3 years
|
|
Total Economic Cost
時間枠：Up to 3 years
|
Total economic cost per participant during the study period, including direct medical costs, non-medical costs, and indirect costs.
Direct medical costs include radiotherapy costs, radiotherapy-related symptomatic treatment costs, and costs for the management of toxic and adverse reactions.
Non-medical and indirect costs include transportation costs, accommodation costs, and lost work or companion time costs.
Costs will be calculated in Chinese Yuan.
|
Up to 3 years
|
|
Quality of Life Score Assessed by EORTC QLQ-C30
時間枠：Up to 3 years
|
Quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30).
The global health status/quality of life score will be recorded at baseline and predefined follow-up visits.
Scores range from 0 to 100, with higher scores indicating better global health status/quality of life.
|
Up to 3 years
|
|
Swallowing Function Score Assessed by the Standardized Swallowing
時間枠：Up to 3 years
|
Swallowing function will be assessed using the Standardized Swallowing Assessment (SSA).
The total SSA score will be recorded at baseline and predefined follow-up visits, with higher scores indicating worse swallowing function.
|
Up to 3 years
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Odds Ratios for Cardiac-Related Disease Occurrence According to Predefined Cardiac and Coronary Artery Dose Parameters
時間枠：From baseline to up to 3 years after radiotherapy
|
Odds ratios for cardiac-related disease occurrence per 1-Gy increase in predefined cardiac and coronary artery dose parameters will be estimated using logistic regression.
Predefined dose parameters will include mean heart dose and coronary artery substructure dose parameters, measured in Gray (Gy) from the radiotherapy treatment plan.
Cardiac-related disease occurrence will be defined as the occurrence of clinically diagnosed cardiac disease or cardiac adverse events during follow-up, assessed by clinical cardiac evaluation and NCI-CTCAE v5.0.
Cardiac-related diseases or adverse events may include coronary artery disease, myocardial ischemia or infarction, arrhythmia, heart failure, pericardial disease, or other clinically diagnosed cardiac events.
|
From baseline to up to 3 years after radiotherapy
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
捜査官
- 主任研究者：Wencheng Zhang, M.D.、Tianjin Medical University Cancer Institute and Hospital
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (推定)
2026年7月14日
一次修了 (推定)
2027年6月30日
研究の完了 (推定)
2029年6月30日
試験登録日
最初に提出
2026年7月1日
QC基準を満たした最初の提出物
2026年7月8日
最初の投稿 (実際)
2026年7月9日
学習記録の更新
投稿された最後の更新 (実際)
2026年7月10日
QC基準を満たした最後の更新が送信されました
2026年7月8日
最終確認日
2026年7月1日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- E20260837
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
いいえ
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。